IPO, M&A delays and more: How government shutdown will affect biopharma

Barring a miraculous last-minute agreement among the two houses of Congress and President Joe Biden, the federal government will run out of money at midnight on Sept. 30, preventing millions of federal workers from reporting for work on Oct. 2 and halting many routine government services and activities.  

As the gears of government slow, the biopharma sector will be inconvenienced but will not be seriously hurt,  unless the funding lapse drags on for an unusually long period of time. ...